RAF/RAS oncogenes and mismatch-repair status
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Genes of the RAF family encode kinases that are regulated by Ras and mediate cellular responses to growth signals. Activating mutations in one RAF gene, BRAF, have been found in a high proportion of melanomas and in a small fraction of other cancers. Here we show that BRAF mutations in colorectal cancers occur only in tumours that do not carry mutations in a RAS gene known as KRAS, and that BRAF mutation is linked to the proficiency of these tumours in repairing mismatched bases in DNA. Our results not only provide genetic support for the idea that mutations in BRAF and KRAS exert equivalent effects in tumorigenesis, but also emphasize the role of repair processes in establishing the mutation spectra that underpin human cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The prevalence of BRAF V600E mutations in mCRC is 8–10%, and they occur only in KRAS-WT mCRC [159,160].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [160]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Lessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Self-citationStabilization of β-Catenin by Genetic Defects in Melanoma Cell Lines
Rubinfeld, B., Robbins, P., El-Gamil, M., Albert, I., Porfiri, E., & Polakis, P. (1997) · Science · doi:10.1126/science.275.5307.1790 · Cited by 1,223
Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer.
Sparks, A. B., Morin, P. J., Vogelstein, B., & Kinzler, K. W. (1998) · PubMed · Cited by 1,008
Self-citationDifferential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases
Marais, R., Light, Y., Paterson, H. F., Mason, C. S., & Marshall, C. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4378 · Cited by 456
Mechanisms underlying losses of heterozygosity in human colorectal cancers
Thiagalingam, S., Laken, S., Willson, J. K. V., Markowitz, S. D., Kinzler, K. W., Vogelstein, B., & Lengauer, C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051625398 · Cited by 228
Self-citationPrevalence of somatic alterations in the colorectal cancer cell genome
Wang, T.-L., Rago, C., Silliman, N., Ptak, J., Markowitz, S., Willson, J. K. V., Parmigiani, G., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261714699 · Cited by 177
Self-citationOncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors
Storm, S. M., & Rapp, U. R. (1993) · Toxicology Letters · doi:10.1016/0378-4274(93)90056-4 · Cited by 53
Research works printed but not linked: 2
- Sparks, A. B., Morin, P. J., Vogelstein, B. & Kinzler, K. W. Cancer Res. 58, 1130–1134 (1998).
- Markowitz, S. J. Clin. Oncol. 18 (suppl.), 75–80 (2000).
Cited by
Items 401–500 of 999
Colorectal cancer and RASSF family—A special emphasis on RASSF1A
Fernandes, M. S., Carneiro, F., Oliveíra, C., & Seruca, R. (2012) · International Journal of Cancer · doi:10.1002/ijc.27696 · Cited by 72
“This review focus on the current knowledge of RASSF inactivation in CRC, particularly RASSF1A, and on the implications RASSFs may have as potential biomarkers and for the development of new targeted therapies for CRC. Colorectal cancer (CRC) is one of the leading causes of cancer mortality worldwide.1 Developing as a…”
BackgroundInfluentialMutational activation of the RAS‐RAF‐MAPK and the wnt pathway in small intestinal adenocarcinomas
Bläker, H., Helmchen, B., Bönisch, A., Aulmann, S., Penzel, R., Otto, H. F., & Rieker, R. J. (2004) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520410005847 · Cited by 67
“KRAS (21), and for exons 11 and 15 of BRAF (18), as previously reported.”
Singh, M., Suman, S., & Shukla, Y. (2014) · BioMed Research International · doi:10.1155/2014/243452 · Cited by 83
Blank, P. R., Moch, H., Szucs, T. D., & Schwenkglenks, M. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2267 · Cited by 73
Mutation‐specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas
Sinicrope, F. A., Smyrk, T. C., Tougeron, D., Thibodeau, S. N., Singh, S., Murányi, A., Shanmugam, K., Grogan, T. M., Alberts, S. R., & Shi, Q. (2013) · Cancer · doi:10.1002/cncr.28133 · Cited by 65
“BRAF and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are mutually exclusive in CRCs.(5,6,14) Evidence suggests that BRAF mutations in advanced CRCs with wild-type KRAS”
BackgroundInfluentialPredictive and Prognostic Markers in Colorectal Cancer
George, B., & Kopetz, S. (2011) · Current Oncology Reports · doi:10.1007/s11912-011-0162-3 · Cited by 71
“However, BRAF mutations have also been reported in a small proportion of patients with MSS colon tumors [ 72 , 73].”
BackgroundConsistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status
Pappa, K. I., Choleza, M., Markaki, S. P., Giannikaki, E., Kyroudi, A., Vlachos, G. D., Voulgaris, Z., & Anagnou, N. P. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.09.029 · Cited by 64
BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
Ros, J., Baraibar, I., Sardo, E., Mulet-Margalef, N., Salvà, F., Argilés, G., Martini, G., Ciardiello, D., Cuadra‐Urteaga, J. L., Tabernero, J. M., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835921992974 · Cited by 76
The Therapeutic Potential of MAPK/ERK Inhibitors in the Treatment of Colorectal Cancer
Pashirzad, M., Khorasanian, R., Fard, M. M., Arjmand, M., Langari, H., Khazaei, M., Soleimanpour, S., Rezayi, M., Ferns, G. A., Hassanian, S. M., et al. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009621666211103113339 · Cited by 74
BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?
Cohen, R., Cervera, P., Svrcek, M., Pellat, A., Dreyer, C., de Gramont, A., & André, T. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0453-5 · Cited by 66
Joseph, R. W., Swaika, A., & Crozier, J. A. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s31143 · Cited by 78
“On the other hand, vemurafenib and other BRAF inhibitors do not generate responses in the 10% of colorectal cancer patients who harbor BRAF mutations, likely secondary to activation of alternate pathways such as the EGFR signaling pathway.(37,92,93) In summary, BRAF mutations occur in multiple malignancies outside of…”
In silico analysis of Single Nucleotide Polymorphisms (SNPs) in human BRAF gene
Hussain, M. R. M., Shaik, N. A., Al-Aama, J. Y., Asfour, H. Z., Khan, F., Masoodi, T., Khan, M. A., & Shaik, N. S. (2012) · Gene · doi:10.1016/j.gene.2012.07.014 · Cited by 67
Molecular predictive and prognostic markers in colon cancer
Winder, T., & Lenz, H. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.03.005 · Cited by 72
“Thus, mismatch repair-deficient tumours have a very high incidence of B-Raf mutations and a lower incidence of K-Ras mutations compared with MMR-proficient colorectal cancers.(41) A recent restrospective trial of 113 patients indicated that occurrence of oncogenic B-Raf alleles negatively interferes with the clinical…”
ResultMcCubrey, J. A., Steelman, L. S., Abrams, S. L., Chappell, W. H., Russo, S., Ove, R., Milella, M., Tafuri, A., Lunghi, P., Bonati, A., et al. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210903282760 · Cited by 63
“In many cancers with BRAF mutations, the mutations are believed to be initiating events, but are not sufficient for full-blown neoplastic transformation [8,12,16,17].”
BackgroundMagudia, K. A., Lahoz, A., & Hall, A. (2012) · The Journal of Cell Biology · doi:10.1083/jcb.201202108 · Cited by 72
“Interestingly, colorectal tumors rarely contain both KRAS and BRAF mutations, although 8% have PI3KCA mutations coexistent with KRAS or BRAF mutations (Rajagopalan et al., 2002; Yuan and Cantley, 2008; Janku et al., 2011).”
18F-FDG PET/CT imaging in rectal cancer: relationship with the RAS mutational status
Lovinfosse, P., Koopmansch, B., Lambert, F., Jodogne, S., Kustermans, G., Hatt, M., Visvikis, D., Seidel, L., Polus, M., Albert, A., et al. (2016) · The British Journal of Radiology · doi:10.1259/bjr.20160212 · Cited by 63
Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening
Walsh, C., Blum, A., Walts, A. E., Alsabeh, R., Tran, H., Koeffler, H. P., & Karlan, B. Y. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.11.021 · Cited by 62
Mizukami, T., Izawa, N., Nakajima, T. E., & Sunakawa, Y. (2019) · Drugs · doi:10.1007/s40265-019-01113-0 · Cited by 65
Molecular markers for colon diagnosis, prognosis and targeted therapy
Herzig, D. O., & Tsikitis, V. L. (2014) · Journal of Surgical Oncology · doi:10.1002/jso.23806 · Cited by 70
“Mutations in the BRAF gene have been involved in CRC tumorigenesis [45,46].”
BackgroundPoor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability
Umeda, Y., Nagasaka, T., Mori, Y., Sadamori, H., Sun, D., Shinoura, S., Yoshida, R., Satoh, D., Nobuoka, D., Utsumi, M., et al. (2012) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1007/s00534-012-0531-9 · Cited by 66
“BRAF mutations were initially identified in CRCs with mismatch repair (MMR) deficiency [18, 25].”
BackgroundRahmani, M., Nguyen, T. K., Dent, P., & Grant, S. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.033308 · Cited by 62
“The Raf pathway, which activates MEK1/2/ERK1/2, is frequently dysregulated in human cancer (Davies et al., 2002; Rajagopalan et al., 2002).”
BackgroundVascular Endothelial Growth Factor
Wedge, S. R., & Jürgensmeier, J. M. (2007) · Springer eBooks · doi:10.1007/978-3-540-33177-3_23 · Cited by 61
Adhesion-dependent Activation of the ERK1/2 Cascade Is By-passed in Melanoma Cells
Conner, S. R., Scott, G., & Aplin, A. E. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305797200 · Cited by 61
KRAS and BRAF mutations in sinonasal cancer
López, F., Inclán, C. G., Pérez‐Escuredo, J., Marcos, C. Á., Scola, B., Suárez, C., Llorente, J. L., & Hermsen, M. A. J. A. (2012) · Oral Oncology · doi:10.1016/j.oraloncology.2012.02.018 · Cited by 64
B-Raf mutation: A key player in molecular biology of cancer
Rahman, M. A., Salajegheh, A., Smith, R. A., & Lam, A. K.-Y. (2013) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2013.10.005 · Cited by 70
Boparai, K. S., Dekker, E., Polak, M. M., Musler, A. R., van Eeden, S., & van Noesel, C. J. M. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.02.023 · Cited by 60
BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma
Affolter, K. E., Samowitz, W. S., Tripp, S. R., & Bronner, M. P. (2013) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22070 · Cited by 59
Impact of primary colorectal Cancer location on the KRAS status and its prognostic value
Xie, M., Li, J., Cai, Z.-M., Li, K., & Hu, B.-L. (2019) · BMC Gastroenterology · doi:10.1186/s12876-019-0965-5 · Cited by 70
Colorectal cancers choosing sides
Albuquerque, C. M., Bakker, E. R. M., van Veelen, W., & Smits, R. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.07.005 · Cited by 69
Control of colorectal metastasis formation by K-Ras
Smakman, N., Rinkes, I. H. M. B., Voest, E. E., & Kranenburg, O. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.07.001 · Cited by 66
Circulating free tumor DNA and colorectal cancer
Lecomte, T., Cézé, N., Dorval, E. D., & Laurent‐Puig, P. (2010) · Gastroentérologie Clinique et Biologique · doi:10.1016/j.gcb.2009.04.015 · Cited by 61
Preto, A., Figueiredo, J., Velho, S., Ribeiro, A., Soares, P., Oliveíra, C., & Seruca, R. (2007) · The Journal of Pathology · doi:10.1002/path.2295 · Cited by 60
“In sporadic CRC with a microsatellite instability (MSI) phenotype due to mismatch repair (MMR) deficiency, BRAF mutations were found in 31–45% of the cases analysed [1,2,5,6].”
BackgroundSchönleben, F., Qiu, W., Allendorf, J., Chabot, J. A., Remotti, H. E., & Su, G. H. (2009) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-009-0917-4 · Cited by 59
Defining the blueprint of the cancer genome
Velculescu, V. E. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn096 · Cited by 65
“Mutations in v-rat murine sarcoma viral oncogene homolog were shown to be mutually exclusive with alterations in the Kirsten rat sarcoma viral oncogene homolog (KRAS) providing genetic evidence that these genes operated in the same pathway in human tumors and suggesting that mutation in either was sufficient to activa…”
BackgroundSelf-citationMolecular Diagnostics of Colorectal Cancer
Bedeir, A., & Krasinskas, A. M. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0613-rair.1 · Cited by 70
Wiersma, V. R., de Bruyn, M., Wei, Y., van Ginkel, R. J., Hirashima, M., Niki, T., Nishi, N., Zhou, J., Pouwels, S. D., Samplonius, D. F., et al. (2015) · Autophagy · doi:10.1080/15548627.2015.1063767 · Cited by 58
“Indeed, although mutated KRAS and BRAF both activate MAP2K/mitogen-activated protein kinase kinases-MAPK/mitogen-activated protein kinase-signaling and disrupt polarity in colon epithelial cells,(5) oncogenic KRAS and BRAF transformations typically occur in a mutually exclusive manner.(46) Therefore, differences in se…”
BackgroundSvrcek, M., Buhard, O., Colas, C., Coulet, F., Dumont, S., Massaoudi, I., Lamri, A., Hamelin, R., Cosnes, J., Oliveíra, C., et al. (2010) · Gut · doi:10.1136/gut.2009.194787 · Cited by 63
“methylation status may be different in distinct regions of the promoter, as described in glioblastoma.”
BackgroundIrimia, M., Fraga, M. F., Sánchez‐Céspedes, M., & Esteller, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207914 · Cited by 58
“Interestingly, BRAF mutations occur most frequently in the context of wild-type K-ras (Rajagopalan et al., 2002; Soares et al., 2003).”
BackgroundDhir, M., Yachida, S., Neste, L. V., Glöckner, S. C., Jeschke, J., Pappou, E. P., Montgomery, E. A., Herman, J. G., Baylin, S. B., Iacobuzio–Donahue, C. A., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25847 · Cited by 57
“This is consistent with the fact that BRAF and KRAS mutations are mutually exclusive.(48) As most of our tested lesions were positive for BRAF, KRAS mutations might be underrepresented in these lesions.”
ResultSaridaki, Z., Tzardi, M. N., Sfakianaki, M., Papadaki, C., Voutsina, A., Kalykaki, A., Messaritakis, I., Mpananis, K., Mavroudis, D., Stathopoulos, E. N., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084604 · Cited by 59
Schweiger, T., Hegedűs, B., Nikolowsky, C., Hegedűs, Z., Szirtes, I., Mair, R., Birner, P., Döme, B., Láng, G., Klepetko, W., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3386-7 · Cited by 62
“They can only be found in less than 10 % of all primary CRCs.(17) In contrast to KRAS Mts, alterations in the BRAF oncogene strongly correlate with shorter progression-free and overall survival.”
Mesteri, I., Bayer, G., Meyer, J., Capper, D., SCHOPPMANN, S. F., von Deimling, A., & Birner, P. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.126 · Cited by 56
Sun, T., Liu, S., Zhou, Y., Yao, Z., Zhang, D., Cao, S., Wei, Z., Tan, B., Li, Y., Lian, Z., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13443 · Cited by 62
Association between clinicopathological characteristics and RAS mutation in colorectal cancer
Rimbert, J., Tachon, G., Junca, A., Villalva, C., Karayan, L., & Tougeron, D. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.119 · Cited by 63
Oliveíra, C., Velho, S., Domingo, E., Preto, A., Hofstra, R. M. W., Hamelin, R., Yamamoto, H., Seruca, R., & Schwartz, S. (2005) · Oncogene · doi:10.1038/sj.onc.1208906 · Cited by 57
“KRAS and BRAF mutations, activating the RAS/ RAF/MAPK pathway, are the most frequent oncogenic events in SCRC (Rajagopalan et al., 2002; Yuen et al., 2002; Oliveira et al., 2003).”
BackgroundUrosevic, J., Blasco, M. T., Lope, A. L., Bellmunt, A., Berenguer, A., Guiu, M., Cañellas-Socias, A., Fernández, E., Burkov, I., Clapés, M., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-4028 · Cited by 61
Mutations of BRAF and RAS are rare events in germ cell tumours
Sommerer, F., Hengge, U. R., Markwarth, A., Vomschloß, S., Stolzenburg, J., Wittekind, C., & Tannapfel, A. (2004) · International Journal of Cancer · doi:10.1002/ijc.20567 · Cited by 56
Fujii, S., Ishibashi, T., Kokura, M., Fujimoto, T., Matsumoto, S., Shidara, S., Kurppa, K. J., Pape, J., Catón, J., Morgan, P. R., et al. (2021) · The Journal of Pathology · doi:10.1002/path.5814 · Cited by 64
“Cancer samples bearing BRAFV600Emutants did not contain RASmutations [34,43], indicating their exclusive relationship.”
BackgroundBiomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others
Bupathi, M., & Wu, C. S.-Y. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.07.03 · Cited by 61
“In the presence of a BRAF V600E MT, the patient likely has loss of MMR genes secondary to sporadic causes (17).”
BackgroundInfluentialten Broeke, S. W., van Bavel, T. C., Jansen, A. M. L., Gómez-García, E. B., Hes, F. J., van Hest, L. P., Letteboer, T. G. W., Olderode-Berends, M. J. W., Ruano, D., Spruijt, L., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.05.020 · Cited by 57
Minimally invasive biomarkers for detection and staging of colorectal cancer
Booth, R. A. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.12.021 · Cited by 56
Tan, L., Tran, B., Tie, J., Markman, B., Ananda, S., Tebbutt, N. C., Michael, M., Link, E. K., Wong, S. Q., Chandrashekar, S., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3094 · Cited by 59
“More than 95% of mutations occur as a V600E change (valine to glutamic acid substitution), and are mutually exclusive with RAS mutations(3,4).”
Targeted Therapy of Colorectal Cancer
Seeber, A., & Gastl, G. A. (2016) · Oncology Research and Treatment · doi:10.1159/000453027 · Cited by 66
Targeted therapy for metastatic colorectal cancer
Price, T. J., Tang, M., Gibbs, P., Haller, D. G., Peeters, M., Arnold, D., Segelov, E., Roy, A. C., Tebbutt, N. C., Pavlakis, N., et al. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1502664 · Cited by 55
Troiani, T., Zappavigna, S., Martinelli, E., Addeo, S. R., Stiuso, P., Ciardiello, F., & Caraglia, M. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.756469 · Cited by 53
“The BRAF V600E mutation occurs in approximately 4 -- 15% of CRC and is known to be mutually exclusive with KRAS in CRC [33].”
BackgroundTime to re‐consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma
Gandolfi, G., Sancisi, V., Piana, S., & Ciarrocchi, A. (2014) · International Journal of Cancer · doi:10.1002/ijc.28976 · Cited by 58
“This mutation and its association with different clinical features has been largely investigated in different tumor settings and in particular in melanoma, colon cancer and thyroid carcinoma (Figure 1) (1-10).”
BackgroundZlobec, I., Baker, K., Terracciano, L. M., & Lugli, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5103 · Cited by 43
Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients
Shen, H., Yuan, Y., Hu, H., Zhong, X., Ye, X.-X., Li, M., Fang, W.-J., & Zheng, S. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i6.809 · Cited by 55
Utilizing protein structure to identify non-random somatic mutations
Ryslik, G. A., Cheng, Y., Cheung, K.-H., Modis, Y., & Zhao, H. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-190 · Cited by 60
Anwar, M. A. F., Murad, F. G., Dawson, E., Elmageed, Z. Y. A., Tsumagari, K., & Kandil, E. H. (2016) · Journal of Surgical Research · doi:10.1016/j.jss.2016.04.029 · Cited by 54
BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation
Nakayama, I., Hirota, T., & Shinozaki, E. (2020) · Cancers · doi:10.3390/cancers12113236 · Cited by 65
“The positive association with microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) tumors and mutual exclusiveness with the KRAS mutation of BRAFV600E-mutated CRC were initially well documented [20].”
BackgroundColorectal Cancer in the Arab World - Screening Practices and Future Prospects
Arafa, M. A., & Farhat, K. H. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.17.7425 · Cited by 54
“…somatic mutations in many different genes, including KRAS, PIK3CA, BRAF, CTNNB1, AXIN2, AKT1, and MCC, have been identified in colorectal cancer (Kinzler et al., 1991; Ilyas et al., 1997; Liu et al., 2000; Rajagopalan et al., 2002; Samuels et al., 2004; Carpten et al., 2007; Misale et al., 2012).”
BackgroundHigh Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer
Jeantet, M., Tougeron, D., Tachon, G., Cortes, U., Archambaut, C., Fromont, G., & Karayan-Tapon, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122015 · Cited by 50
“KRAS, NRAS and BRAF mutations are considered to be mutually exclusive in CRC [16].”
BackgroundLin, Y., & Zhen, Y. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3283182913 · Cited by 51
Maestro, M. L., Vidaurreta, M., Casla, M. T. S., Rafael, S., Veganzones, S., Martínez, A., Aguilera, C., Herranz, M., Cerdán, J., & Arroyo, M. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9111-z · Cited by 51
Bouzourène, H., Hutter, P., Losi, L., Martin, P., & Benhattar, J. (2009) · Familial Cancer · doi:10.1007/s10689-009-9302-4 · Cited by 53
“Recently, activating mutations in the BRAF protooncogene have been associated with MSI-H tumours in general [ 25 ], and subsequently with the sporadic subset in particular, providing a further avenue for distinction between familial and sporadic MSI-H tumours [26‐29].”
BackgroundMutational status of naevus-associated melanomas
Shitara, D. I., Tell‐Martí, G., Bádenas, C., Enokihara, M. M. S. S., Alós, L., Larque, A. B., Michalany, N. S., Puig‐Butillé, J. A., Carrera, C., Malvehy, J., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.13829 · Cited by 56
Composite regulation of ERK activity dynamics underlying tumour-specific traits in the intestine
Muta, Y., Fujita, Y., Sumiyama, K., Sakurai, A., Taketo, M. M., Chiba, T., Seno, H., Aoki, K., Matsuda, M., & Imajo, M. (2018) · Nature Communications · doi:10.1038/s41467-018-04527-8 · Cited by 50
Sanaei, M., Khorasani, A. B. S., Pourbagheri‐Sigaroodi, A., Shahrokh, S., Zali, M. R., & Bashash, D. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30655 · Cited by 62
“Accordingly, the majority of BRAF mutations were shown in almost 5% and 50% of microsatellite stable cases and microsatellite unstable colorectal tumors, respectively (Domingo et al., 2004; Loughrey et al., 2007; Rajagopalan et al., 2002; Samowitz et al., 2005).”
BackgroundBRAF kinase in melanoma development and progression
DeLuca, A. M., Srinivas, A., & Alani, R. M. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000604 · Cited by 58
Perkins, G., Lièvre, A., Ramacci, C., Méatchi, T., de Reynies, A., Emile, J., Boige, V., Tomasic, G., Bachet, J., Bibeau, F., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25152 · Cited by 49
Patil, D. T., Shadrach, B. L., Rybicki, L. A., Heald, B., & Pai, R. K. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.98 · Cited by 58
Banno (2009) · International Journal of Oncology · doi:10.3892/ijo_00000283 · Cited by 49
Overexpression of GLUT1 in Colorectal Cancer is Independently Associated with Poor Prognosis
Shen, Y., Arbman, G., Olsson, B., & Sun, X. (2011) · The International Journal of Biological Markers · doi:10.5301/jbm.2011.8550 · Cited by 52
BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms
Ikehara, N., Semba, S., Sakashita, M., Aoyama, N., Kasuga, M., & Yokozaki, H. (2005) · International Journal of Cancer · doi:10.1002/ijc.20957 · Cited by 56
Hypermethylation of CpG island loci of multiple tumor suppressor genes in retinoblastoma
Cohen, Y., Merhavi-Shoham, E., Avraham, R. B., Frenkel, S., Pe’er, J., & Goldenberg‐Cohen, N. (2008) · Experimental Eye Research · doi:10.1016/j.exer.2007.10.010 · Cited by 49
Guedes, J. G., Veiga, I., Rocha, P., Pinto, P., Pinto, C., Pinheiro, M., Peixoto, A., Fragoso, M., Raimundo, A. C., Ferreira, P., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-169 · Cited by 51
“Since the BRAF p.Val600Glu mutation is associated with microsatellite instability (MSI) status and right colon tumors [31-33], variations in sample characteristics between studies can account for the wide frequency range, but this is often hard to verify as many studies in mCRC do not describe the…”
Packham, D., Ward, R. L., Lin, V. A., Hawkins, N. J., & Hitchins, M. P. (2009) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e318182af52 · Cited by 50
“2%, as detected by a combination of real-time allele-specific PCR and pyrosequencing, consistent with other reports.(2,3) Use of the novel KRAS pyrosequencing assays identified KRAS mutations in 32.”
BackgroundResultBirgisson, H., Edlund, K., Wallin, U., Påhlman, L., Kultima, H. G., Mayrhofer, M., Micke, P., Isaksson, A., Botling, J., Glimelius, B. L. G., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1144-x · Cited by 50
“BRAF and KRAS mutations were confirmed to be mutually exclusive in this study, as previously reported [46].”
ResultDNA Methylation and Cancer Pathways in Gastrointestinal Tumors
Suzuki, H., Tokino, T., Shinomura, Y., Imai, K., & Toyota, M. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.12.1917 · Cited by 50
de Abajo, A. S., de la Hoya, M., van Puijenbroek, M., Tosar, A., López-Asenjo, J. A., Díaz‐Rubio, E., Morreau, H. M., & Caldés, T. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2996 · Cited by 47
Chen, J., Jin, Y., Zhai, Y., Qiong, Q., & Zhou, J. (2016) · Oncotarget · doi:10.18632/oncotarget.10151 · Cited by 52
“Furthermore, AREG and EREG did not have predictive value in patients with KRAS mutations, indicating that other oncogenic intracellular signaling pathways, including non-RAS-RAF-MAPK pathways, are activated in KRAS-MT mCRC [40].”
BackgroundRole of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab
Jacome, A. A. D. A., & Eng, C. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1680636 · Cited by 48
p53 mutation is common in microsatellite stable, BRAF mutant colorectal cancers
Bond, C., Umapathy, A., Ramsnes, I., Greco, S. A., Zhao, Z., Mallitt, K., Buttenshaw, R. L., Montgomery, G. W., Leggett, B., & Whitehall, V. (2011) · International Journal of Cancer · doi:10.1002/ijc.26175 · Cited by 53
“It is inversely correlated with mutation of KRAS, which functions upstream of BRAF in the MAPK pathway.(7) The BRAF V600E mutation is strongly associated with the serrated pathway from an early stage as it has been found in serrated hyperplastic aberrant crypt foci (ACF).”
BackgroundInfluentialExon 15 BRAF mutations are uncommon in canine oral malignant melanomas
Shelly, S., Chien, M. B., Yip, B., Kent, M. S., Théon, A. P., McCallan, J. L., & London, C. A. (2005) · Mammalian Genome · doi:10.1007/s00335-004-2441-x · Cited by 59
“…of human cancers, including colon cancer, papillary thyroid carcinomas, and malignant melanoma, have been shown to exhibit BRAF dysregulation (Brose et al. 2002; Davies et al. 2002; Rajagopalan et al. 2002; Yuen et al. 2002; Kimura et al. 2003; Nikiforova et al. 2003; Satyamoorthy et al. 2003).”
BackgroundMutational analysis of gene families in human cancer
Bardelli, A., & Velculescu, V. E. (2004) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.009 · Cited by 48
Self-citationGharib, E., & Robichaud, G. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179463 · Cited by 65
Low frequency of BRAF and CDKN2A mutations in endometrial cancer
Salvesen, H. B., Kumar, R., Stefansson, I. M., Angelini, S., MacDonald, N., Smeds, J., Jacobs, I. J., Hemminki, K., Das, S., & Akslen, L. A. (2005) · International Journal of Cancer · doi:10.1002/ijc.20702 · Cited by 46
“Mutations in BRAF have been reported in melanomas, colorectal cancers and ovarian tumours.(3,4) These mutations of BRAF have also been linked to microsatellite instability (MSI) in colorectal carcinoma.”
BackgroundSignificance of serrated polyps of the colon
Groff, R. J., Nash, R., & Ahnen, D. J. (2008) · Current Gastroenterology Reports · doi:10.1007/s11894-008-0090-z · Cited by 46
KRAS mutation testing in clinical practice
Perincheri, S., & Hui, P. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.986102 · Cited by 48
Exploring Different Strategies for Efficient Delivery of Colorectal Cancer Therapy
Lin, C., Ng, H., Pan, W., Chen, H., Zhang, G., Bian, Z., Lü, A., & Yang, Z. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161125995 · Cited by 53
“Oncogenes DNA mismatch-repair defects RAS, BRAF 13–37 Activates the mitogen-activated protein kinase signaling pathway [47–49].”
BackgroundEnhancement of 5-Fluorouracil-induced In Vitro and In Vivo Radiosensitization with MEK Inhibition
Urick, M. E., Chung, E. J., Shield, W. P., Gerber, N. K., White, A. O., Sowers, A. L., Thetford, A., Camphausen, K. A., Mitchell, J. B., & Citrin, D. E. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0358 · Cited by 46
“Selumetinib has broad preclinical activity with increased single agent efficacy in cancer cell lines with BRaf or KRas mutations (24).”
InfluentialNakaji, Y., Oki, E., Nakanishi, R., Ando, K., Sugiyama, M., Nakashima, Y., Yamashita, N., Saeki, H., Oda, Y., & Maehara, Y. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2275-4 · Cited by 44
Bond, C., & Whitehall, V. (2018) · Gastroenterology Research and Practice · doi:10.1155/2018/9250757 · Cited by 54
“The class 1 BRAF V600E mutation and also class 2 mutations allow for constitutive activation of the pathway; therefore, a concurrent KRAS mutation is redundant which is indicated by the mutual exclusivity of these two mutation types occurring in a single cancer [1, 29].”
InfluentialMolecular genetics of colorectal cancer: An overview
Hisamuddin, I. M., & Yang, V. W. (2006) · Current Colorectal Cancer Reports · doi:10.1007/s11888-006-0002-2 · Cited by 65
An Update on the Biology of RAS/RAF Mutations in Colorectal Cancer
Nandan, M. O., & Yang, V. W. (2011) · Current Colorectal Cancer Reports · doi:10.1007/s11888-011-0086-1 · Cited by 57
“It was previously found that mutations in the B-RAF gene were prevalent in several cancers including melanomas, colorectal cancers, and ovarian tumors [53, 54 ].”
BackgroundThe CpG Island Methylator Phenotype in Colorectal Cancer
Samowitz, W. S. (2007) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2007.070031 · Cited by 46
Chakraborty, J., Chakraborty, S., Chakraborty, S., & Narayan, M. (2023) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2023.194988 · Cited by 53
Vilkin, A., Niv, Y., Nagasaka, T., Morgenstern, S., Levi, Z., Fireman, Z., Fuerst, F. C., Goel, A., & Boland, C. R. (2009) · Cancer · doi:10.1002/cncr.24019 · Cited by 45
“Recently, BRAF mutation was described in a small percentage of MSS tumors but in 50% of MSI-H tumors, particularly in tumors with methylation of the MLH1 promoter.(12,17) To our knowledge, a BRAF mutation has never been described in tumors with germline mutations of the MLH1 gene.”
BackgroundContribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer
Sinicrope, F. A., Shi, Q., Hermitte, F., Zemla, T., Mlecnik, B., Benson, A. B., Gill, S., Goldberg, R. M., Kahlenberg, M. S., Nair, S., et al. (2020) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaa023 · Cited by 48
“BRAF and KRAS were analyzed as a combined variable because mutations in these genes are nearly always mutually exclusive within a given tumor (23).”
Background
Metadata
- Authors
- Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E.
- Affiliations
- Johns Hopkins University (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Velculescu, Victor E.
- Venue
- Nature
- Published
- 2002-08-29
- Volume
- 418
- Issue
- 6901
- Pages
- 934-934
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1985035689
- Cited by
- 1,224
- References
- 8
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 29 · 2023: 30 · 2022: 26 · 2021: 42 · 2020: 38 · 2019: 35 · 2018: 41 · 2017: 42 · 2016: 51 · 2015: 76 · 2014: 65 · 2013: 74 · 2012: 78
- FWCI
- 37.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- BRAF mutation, KRAS mutation, oncogenic Ras, DNA mismatch repair, colorectal cancer, melanoma, carcinogenesis, DNA repair, mutation spectrum, growth factor signaling
- MeSH terms
- DNA Damage, DNA Repair, Gene Frequency, Humans, Mutation, Oncogenes, Genes, ras, Colorectal Neoplasms, Proto-Oncogene Proteins c-raf, Base Pair Mismatch
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.